YIRUI Pharma Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
22
- Latest Deal Type
-
Series A2
- Latest Deal Amount
-
$14.7M
- Investors
-
7
YIRUI Pharma General Information
Description
Developer of small molecule innovative targeted drugs designed for the treatment of autoimmune and chronic inflammatory diseases. The company focuses on the research and development of highly selective ion channel inhibitors, including its lead candidate yr001, intended to provide first-line therapeutic solutions for atopic dermatitis, psoriasis, and diabetic complications through both topical and oral administration methods.
Contact Information
Website
www.yirui-pharma.comCorporate Office
- Room 201, Building 2, Pharmaceutical Port
- Number 291 Fucheng Road, Xiasha Street, Qiantang New District
- Hangzhou, Zhejiang 310000
- China
Corporate Office
- Room 201, Building 2, Pharmaceutical Port
- Number 291 Fucheng Road, Xiasha Street, Qiantang New District
- Hangzhou, Zhejiang 310000
- China
YIRUI Pharma Timeline
YIRUI Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series A2) | 14-May-2026 | $14.7M | Completed | Generating Revenue | ||
| 2. Later Stage VC (Series A1) | 26-Oct-2023 | Completed | Generating Revenue | |||
| 1. Early Stage VC (Series A) | 29-Jun-2022 | $5.23M | $5.23M | Completed | Generating Revenue |
YIRUI Pharma Patents
YIRUI Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026200879-A1 | Trpc6 inhibitor and preparation method therefor and use thereof | Pending | 27-Mar-2025 | ||
| EP-4834884-A1 | Trpv3 inhibitor, and preparation therefor and use thereof | Pending | 29-Dec-2023 | ||
| WO-2025139868-A1 | Trpv3 inhibitor, and preparation therefor and use thereof | Inactive | 29-Dec-2023 | ||
| EP-4538261-A1 | N-tetrazolyl aryl urea derivatives, preparation method therefor, and use thereof | Pending | 07-Jun-2022 | ||
| EP-4538261-A4 | N-tetrazolyl aryl urea derivatives, preparation method therefor, and use thereof | Pending | 07-Jun-2022 | C07D405/12 |
YIRUI Pharma Signals
YIRUI Pharma Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Hangzhou Chaosheng Investment Management | Growth/Expansion | Minority | ||
| Ordos Group | Corporation | Minority | ||
| Hangzhou Shenghui Jingchen Investment Management | Growth/Expansion | Minority | ||
| Hangzhou Tailong Venture Capital Partnership | Growth/Expansion | Minority | ||
| Hangzhou Tigermed Consulting Company | Corporation | Minority |
YIRUI Pharma FAQs
-
When was YIRUI Pharma founded?
YIRUI Pharma was founded in 2018.
-
Where is YIRUI Pharma headquartered?
YIRUI Pharma is headquartered in Hangzhou, China.
-
What is the size of YIRUI Pharma?
YIRUI Pharma has 22 total employees.
-
What industry is YIRUI Pharma in?
YIRUI Pharma’s primary industry is Drug Discovery.
-
Is YIRUI Pharma a private or public company?
YIRUI Pharma is a Private company.
-
What is YIRUI Pharma’s current revenue?
The current revenue for YIRUI Pharma is .
-
How much funding has YIRUI Pharma raised over time?
YIRUI Pharma has raised $19.9M.
-
Who are YIRUI Pharma’s investors?
Hangzhou Chaosheng Investment Management, Ordos Group, Hangzhou Shenghui Jingchen Investment Management, Hangzhou Tailong Venture Capital Partnership, and Hangzhou Tigermed Consulting Company are 5 of 7 investors who have invested in YIRUI Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process